English
简体中文
Total: £ 56.28
Published Date: 2026-01-22 | Pages: 134 | Tables: 133 | Pharma & Healthcare
The global Pelvic Cancer Drug market was valued at US$ 1292 million in 2025 and is anticipated to reach US$ 2657 million by 2032, at a CAGR of 11.0% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Pelvic Cancer Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Pelvic cancer drugs refer to pharmaceutical treatments that are used to manage or treat cancers affecting the pelvic area. The pelvic region houses several organs, including the bladder, rectum, reproductive organs (such as the uterus, ovaries, prostate, and testes), and lymph nodes. Cancers that develop in these organs may be classified into different types, and the drugs used for their treatment depend on the specific type of cancer, its stage, and other factors.
The North American market for Pelvic Cancer Drug is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Pelvic Cancer Drug is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Pelvic Cancer Drug include F. Hoffmann-La Roche Ltd, Pfizer Inc., GSK plc, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Alnylam Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Pelvic Cancer Drug market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pelvic Cancer Drug. The Pelvic Cancer Drug market size, estimates, and forecasts are provided in terms of sales volume (kg) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Pelvic Cancer Drug market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Pelvic Cancer Drug manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd
Pfizer Inc.
GSK plc
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb Company
Merck & Co., Inc.
Novartis AG
Alnylam Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
Advaxis, Inc.
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
Biocon
AbbVie Inc.
Siemens Healthineers
Gilead Sciences, Inc.
Sanofi
Bayer AG
Segment by Type
Kidney Cancer
Uterus Cancer
Cervical Cancer
by Application
Chemotherapy
Radiation Therapy
Targeted Therapy
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Pelvic Cancer Drug manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Pelvic Cancer Drug sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Pelvic Cancer Drug Market Overview
1.1 Product Definition
1.2 Pelvic Cancer Drug by Type
1.2.1 Global Pelvic Cancer Drug Market Value by Type: 2025 vs 2032
1.2.2 Kidney Cancer
1.2.3 Uterus Cancer
1.2.4 Cervical Cancer
1.3 Pelvic Cancer Drug by Application
1.3.1 Global Pelvic Cancer Drug Market Value by Application: 2025 vs 2032
1.3.2 Chemotherapy
1.3.3 Radiation Therapy
1.3.4 Targeted Therapy
1.4 Global Pelvic Cancer Drug Market Size Estimates and Forecasts
1.4.1 Global Pelvic Cancer Drug Revenue 2021–2032
1.4.2 Global Pelvic Cancer Drug Sales 2021–2032
1.4.3 Global Pelvic Cancer Drug Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Pelvic Cancer Drug Market Competition by Manufacturers
2.1 Global Pelvic Cancer Drug Sales Market Share by Manufacturers (2021–2026)
2.2 Global Pelvic Cancer Drug Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Pelvic Cancer Drug Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Pelvic Cancer Drug, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Pelvic Cancer Drug, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Pelvic Cancer Drug, Product Types and Applications
2.7 Global Key Manufacturers of Pelvic Cancer Drug, Date of Entry into the Industry
2.8 Global Pelvic Cancer Drug Market Competitive Situation and Trends
2.8.1 Global Pelvic Cancer Drug Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Pelvic Cancer Drug Players Market Share by Revenue
2.8.3 Global Pelvic Cancer Drug Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pelvic Cancer Drug Market Scenario by Region
3.1 Global Pelvic Cancer Drug Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Pelvic Cancer Drug Sales by Region: 2021–2032
3.2.1 Global Pelvic Cancer Drug Sales by Region: 2021–2026
3.2.2 Global Pelvic Cancer Drug Sales by Region: 2027–2032
3.3 Global Pelvic Cancer Drug Revenue by Region: 2021–2032
3.3.1 Global Pelvic Cancer Drug Revenue by Region: 2021–2026
3.3.2 Global Pelvic Cancer Drug Revenue by Region: 2027–2032
3.4 North America Pelvic Cancer Drug Market Facts & Figures by Country
3.4.1 North America Pelvic Cancer Drug Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Pelvic Cancer Drug Sales by Country (2021–2032)
3.4.3 North America Pelvic Cancer Drug Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pelvic Cancer Drug Market Facts & Figures by Country
3.5.1 Europe Pelvic Cancer Drug Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Pelvic Cancer Drug Sales by Country (2021–2032)
3.5.3 Europe Pelvic Cancer Drug Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pelvic Cancer Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Pelvic Cancer Drug Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Pelvic Cancer Drug Sales by Region (2021–2032)
3.6.3 Asia Pacific Pelvic Cancer Drug Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Pelvic Cancer Drug Market Facts & Figures by Country
3.7.1 Latin America Pelvic Cancer Drug Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Pelvic Cancer Drug Sales by Country (2021–2032)
3.7.3 Latin America Pelvic Cancer Drug Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Pelvic Cancer Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Pelvic Cancer Drug Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Pelvic Cancer Drug Sales by Country (2021–2032)
3.8.3 Middle East and Africa Pelvic Cancer Drug Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pelvic Cancer Drug Sales by Type (2021–2032)
4.1.1 Global Pelvic Cancer Drug Sales by Type (2021–2026)
4.1.2 Global Pelvic Cancer Drug Sales by Type (2027–2032)
4.1.3 Global Pelvic Cancer Drug Sales Market Share by Type (2021–2032)
4.2 Global Pelvic Cancer Drug Revenue by Type (2021–2032)
4.2.1 Global Pelvic Cancer Drug Revenue by Type (2021–2026)
4.2.2 Global Pelvic Cancer Drug Revenue by Type (2027–2032)
4.2.3 Global Pelvic Cancer Drug Revenue Market Share by Type (2021–2032)
4.3 Global Pelvic Cancer Drug Price by Type (2021–2032)
5 Segment by Application
5.1 Global Pelvic Cancer Drug Sales by Application (2021–2032)
5.1.1 Global Pelvic Cancer Drug Sales by Application (2021–2026)
5.1.2 Global Pelvic Cancer Drug Sales by Application (2027–2032)
5.1.3 Global Pelvic Cancer Drug Sales Market Share by Application (2021–2032)
5.2 Global Pelvic Cancer Drug Revenue by Application (2021–2032)
5.2.1 Global Pelvic Cancer Drug Revenue by Application (2021–2026)
5.2.2 Global Pelvic Cancer Drug Revenue by Application (2027–2032)
5.2.3 Global Pelvic Cancer Drug Revenue Market Share by Application (2021–2032)
5.3 Global Pelvic Cancer Drug Price by Application (2021–2032)
6 Key Companies Profiled
6.1 F. Hoffmann-La Roche Ltd
6.1.1 F. Hoffmann-La Roche Ltd Company Information
6.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.1.3 F. Hoffmann-La Roche Ltd Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 F. Hoffmann-La Roche Ltd Pelvic Cancer Drug Product Portfolio
6.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.2 Pfizer Inc.
6.2.1 Pfizer Inc. Company Information
6.2.2 Pfizer Inc. Description and Business Overview
6.2.3 Pfizer Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Inc. Pelvic Cancer Drug Product Portfolio
6.2.5 Pfizer Inc. Recent Developments/Updates
6.3 GSK plc
6.3.1 GSK plc Company Information
6.3.2 GSK plc Description and Business Overview
6.3.3 GSK plc Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 GSK plc Pelvic Cancer Drug Product Portfolio
6.3.5 GSK plc Recent Developments/Updates
6.4 Eli Lilly and Company
6.4.1 Eli Lilly and Company Company Information
6.4.2 Eli Lilly and Company Description and Business Overview
6.4.3 Eli Lilly and Company Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Eli Lilly and Company Pelvic Cancer Drug Product Portfolio
6.4.5 Eli Lilly and Company Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 AstraZeneca Pelvic Cancer Drug Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Bristol-Myers Squibb Company
6.6.1 Bristol-Myers Squibb Company Company Information
6.6.2 Bristol-Myers Squibb Company Description and Business Overview
6.6.3 Bristol-Myers Squibb Company Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Bristol-Myers Squibb Company Pelvic Cancer Drug Product Portfolio
6.6.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.7 Merck & Co., Inc.
6.7.1 Merck & Co., Inc. Company Information
6.7.2 Merck & Co., Inc. Description and Business Overview
6.7.3 Merck & Co., Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Merck & Co., Inc. Pelvic Cancer Drug Product Portfolio
6.7.5 Merck & Co., Inc. Recent Developments/Updates
6.8 Novartis AG
6.8.1 Novartis AG Company Information
6.8.2 Novartis AG Description and Business Overview
6.8.3 Novartis AG Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Novartis AG Pelvic Cancer Drug Product Portfolio
6.8.5 Novartis AG Recent Developments/Updates
6.9 Alnylam Pharmaceuticals, Inc.
6.9.1 Alnylam Pharmaceuticals, Inc. Company Information
6.9.2 Alnylam Pharmaceuticals, Inc. Description and Business Overview
6.9.3 Alnylam Pharmaceuticals, Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Alnylam Pharmaceuticals, Inc. Pelvic Cancer Drug Product Portfolio
6.9.5 Alnylam Pharmaceuticals, Inc. Recent Developments/Updates
6.10 Boehringer Ingelheim International GmbH
6.10.1 Boehringer Ingelheim International GmbH Company Information
6.10.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.10.3 Boehringer Ingelheim International GmbH Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Boehringer Ingelheim International GmbH Pelvic Cancer Drug Product Portfolio
6.10.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
6.11 Advaxis, Inc.
6.11.1 Advaxis, Inc. Company Information
6.11.2 Advaxis, Inc. Description and Business Overview
6.11.3 Advaxis, Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Advaxis, Inc. Pelvic Cancer Drug Product Portfolio
6.11.5 Advaxis, Inc. Recent Developments/Updates
6.12 Teva Pharmaceutical Industries Ltd.
6.12.1 Teva Pharmaceutical Industries Ltd. Company Information
6.12.2 Teva Pharmaceutical Industries Ltd. Description and Business Overview
6.12.3 Teva Pharmaceutical Industries Ltd. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Teva Pharmaceutical Industries Ltd. Pelvic Cancer Drug Product Portfolio
6.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.13 Johnson & Johnson Services, Inc.
6.13.1 Johnson & Johnson Services, Inc. Company Information
6.13.2 Johnson & Johnson Services, Inc. Description and Business Overview
6.13.3 Johnson & Johnson Services, Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Johnson & Johnson Services, Inc. Pelvic Cancer Drug Product Portfolio
6.13.5 Johnson & Johnson Services, Inc. Recent Developments/Updates
6.14 Biocon
6.14.1 Biocon Company Information
6.14.2 Biocon Description and Business Overview
6.14.3 Biocon Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Biocon Pelvic Cancer Drug Product Portfolio
6.14.5 Biocon Recent Developments/Updates
6.15 AbbVie Inc.
6.15.1 AbbVie Inc. Company Information
6.15.2 AbbVie Inc. Description and Business Overview
6.15.3 AbbVie Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 AbbVie Inc. Pelvic Cancer Drug Product Portfolio
6.15.5 AbbVie Inc. Recent Developments/Updates
6.16 Siemens Healthineers
6.16.1 Siemens Healthineers Company Information
6.16.2 Siemens Healthineers Description and Business Overview
6.16.3 Siemens Healthineers Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Siemens Healthineers Pelvic Cancer Drug Product Portfolio
6.16.5 Siemens Healthineers Recent Developments/Updates
6.17 Gilead Sciences, Inc.
6.17.1 Gilead Sciences, Inc. Company Information
6.17.2 Gilead Sciences, Inc. Description and Business Overview
6.17.3 Gilead Sciences, Inc. Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Gilead Sciences, Inc. Pelvic Cancer Drug Product Portfolio
6.17.5 Gilead Sciences, Inc. Recent Developments/Updates
6.18 Sanofi
6.18.1 Sanofi Company Information
6.18.2 Sanofi Description and Business Overview
6.18.3 Sanofi Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Sanofi Pelvic Cancer Drug Product Portfolio
6.18.5 Sanofi Recent Developments/Updates
6.19 Bayer AG
6.19.1 Bayer AG Company Information
6.19.2 Bayer AG Description and Business Overview
6.19.3 Bayer AG Pelvic Cancer Drug Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Bayer AG Pelvic Cancer Drug Product Portfolio
6.19.5 Bayer AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pelvic Cancer Drug Industry Chain Analysis
7.2 Pelvic Cancer Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pelvic Cancer Drug Production Mode & Process Analysis
7.4 Pelvic Cancer Drug Sales and Marketing
7.4.1 Pelvic Cancer Drug Sales Channels
7.4.2 Pelvic Cancer Drug Distributors
7.5 Pelvic Cancer Drug Customer Analysis
8 Pelvic Cancer Drug Market Dynamics
8.1 Pelvic Cancer Drug Industry Trends
8.2 Pelvic Cancer Drug Market Drivers
8.3 Pelvic Cancer Drug Market Challenges
8.4 Pelvic Cancer Drug Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Pelvic Cancer Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Pelvic Cancer Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Pelvic Cancer Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Pelvic Cancer Drug Sales (kg) of Key Manufacturers (2021–2026)
Table 5. Global Pelvic Cancer Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Pelvic Cancer Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Pelvic Cancer Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Pelvic Cancer Drug Average Price (US$/g) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Pelvic Cancer Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Pelvic Cancer Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Pelvic Cancer Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Pelvic Cancer Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pelvic Cancer Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Pelvic Cancer Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pelvic Cancer Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Pelvic Cancer Drug Sales by Region (kg), 2021–2026
Table 18. Global Pelvic Cancer Drug Sales Market Share by Region (2021–2026)
Table 19. Global Pelvic Cancer Drug Sales by Region (kg), 2027–2032
Table 20. Global Pelvic Cancer Drug Sales Market Share by Region (2027–2032)
Table 21. Global Pelvic Cancer Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Pelvic Cancer Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Pelvic Cancer Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Pelvic Cancer Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Pelvic Cancer Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Pelvic Cancer Drug Sales by Country (kg), 2021–2026
Table 27. North America Pelvic Cancer Drug Sales by Country (kg), 2027–2032
Table 28. North America Pelvic Cancer Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Pelvic Cancer Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Pelvic Cancer Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Pelvic Cancer Drug Sales by Country (kg), 2021–2026
Table 32. Europe Pelvic Cancer Drug Sales by Country (kg), 2027–2032
Table 33. Europe Pelvic Cancer Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Pelvic Cancer Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Pelvic Cancer Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Pelvic Cancer Drug Sales by Region (kg), 2021–2026
Table 37. Asia Pacific Pelvic Cancer Drug Sales by Region (kg), 2027–2032
Table 38. Asia Pacific Pelvic Cancer Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Pelvic Cancer Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Pelvic Cancer Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Pelvic Cancer Drug Sales by Country (kg), 2021–2026
Table 42. Latin America Pelvic Cancer Drug Sales by Country (kg), 2027–2032
Table 43. Latin America Pelvic Cancer Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Pelvic Cancer Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Pelvic Cancer Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Pelvic Cancer Drug Sales by Country (kg), 2021–2026
Table 47. Middle East and Africa Pelvic Cancer Drug Sales by Country (kg), 2027–2032
Table 48. Middle East and Africa Pelvic Cancer Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Pelvic Cancer Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Pelvic Cancer Drug Sales (kg) by Type (2021–2026)
Table 51. Global Pelvic Cancer Drug Sales (kg) by Type (2027–2032)
Table 52. Global Pelvic Cancer Drug Sales Market Share by Type (2021–2026)
Table 53. Global Pelvic Cancer Drug Sales Market Share by Type (2027–2032)
Table 54. Global Pelvic Cancer Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Pelvic Cancer Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Pelvic Cancer Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Pelvic Cancer Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Pelvic Cancer Drug Price (US$/g) by Type (2021–2026)
Table 59. Global Pelvic Cancer Drug Price (US$/g) by Type (2027–2032)
Table 60. Global Pelvic Cancer Drug Sales (kg) by Application (2021–2026)
Table 61. Global Pelvic Cancer Drug Sales (kg) by Application (2027–2032)
Table 62. Global Pelvic Cancer Drug Sales Market Share by Application (2021–2026)
Table 63. Global Pelvic Cancer Drug Sales Market Share by Application (2027–2032)
Table 64. Global Pelvic Cancer Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Pelvic Cancer Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Pelvic Cancer Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Pelvic Cancer Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Pelvic Cancer Drug Price (US$/g) by Application (2021–2026)
Table 69. Global Pelvic Cancer Drug Price (US$/g) by Application (2027–2032)
Table 70. F. Hoffmann-La Roche Ltd Company Information
Table 71. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 72. F. Hoffmann-La Roche Ltd Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 73. F. Hoffmann-La Roche Ltd Pelvic Cancer Drug Product
Table 74. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 75. Pfizer Inc. Company Information
Table 76. Pfizer Inc. Description and Business Overview
Table 77. Pfizer Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 78. Pfizer Inc. Pelvic Cancer Drug Product
Table 79. Pfizer Inc. Recent Developments/Updates
Table 80. GSK plc Company Information
Table 81. GSK plc Description and Business Overview
Table 82. GSK plc Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 83. GSK plc Pelvic Cancer Drug Product
Table 84. GSK plc Recent Developments/Updates
Table 85. Eli Lilly and Company Company Information
Table 86. Eli Lilly and Company Description and Business Overview
Table 87. Eli Lilly and Company Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 88. Eli Lilly and Company Pelvic Cancer Drug Product
Table 89. Eli Lilly and Company Recent Developments/Updates
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 93. AstraZeneca Pelvic Cancer Drug Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Bristol-Myers Squibb Company Company Information
Table 96. Bristol-Myers Squibb Company Description and Business Overview
Table 97. Bristol-Myers Squibb Company Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 98. Bristol-Myers Squibb Company Pelvic Cancer Drug Product
Table 99. Bristol-Myers Squibb Company Recent Developments/Updates
Table 100. Merck & Co., Inc. Company Information
Table 101. Merck & Co., Inc. Description and Business Overview
Table 102. Merck & Co., Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 103. Merck & Co., Inc. Pelvic Cancer Drug Product
Table 104. Merck & Co., Inc. Recent Developments/Updates
Table 105. Novartis AG Company Information
Table 106. Novartis AG Description and Business Overview
Table 107. Novartis AG Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 108. Novartis AG Pelvic Cancer Drug Product
Table 109. Novartis AG Recent Developments/Updates
Table 110. Alnylam Pharmaceuticals, Inc. Company Information
Table 111. Alnylam Pharmaceuticals, Inc. Description and Business Overview
Table 112. Alnylam Pharmaceuticals, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 113. Alnylam Pharmaceuticals, Inc. Pelvic Cancer Drug Product
Table 114. Alnylam Pharmaceuticals, Inc. Recent Developments/Updates
Table 115. Boehringer Ingelheim International GmbH Company Information
Table 116. Boehringer Ingelheim International GmbH Description and Business Overview
Table 117. Boehringer Ingelheim International GmbH Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 118. Boehringer Ingelheim International GmbH Pelvic Cancer Drug Product
Table 119. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 120. Advaxis, Inc. Company Information
Table 121. Advaxis, Inc. Description and Business Overview
Table 122. Advaxis, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 123. Advaxis, Inc. Pelvic Cancer Drug Product
Table 124. Advaxis, Inc. Recent Developments/Updates
Table 125. Teva Pharmaceutical Industries Ltd. Company Information
Table 126. Teva Pharmaceutical Industries Ltd. Description and Business Overview
Table 127. Teva Pharmaceutical Industries Ltd. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 128. Teva Pharmaceutical Industries Ltd. Pelvic Cancer Drug Product
Table 129. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 130. Johnson & Johnson Services, Inc. Company Information
Table 131. Johnson & Johnson Services, Inc. Description and Business Overview
Table 132. Johnson & Johnson Services, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 133. Johnson & Johnson Services, Inc. Pelvic Cancer Drug Product
Table 134. Johnson & Johnson Services, Inc. Recent Developments/Updates
Table 135. Biocon Company Information
Table 136. Biocon Description and Business Overview
Table 137. Biocon Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 138. Biocon Pelvic Cancer Drug Product
Table 139. Biocon Recent Developments/Updates
Table 140. AbbVie Inc. Company Information
Table 141. AbbVie Inc. Description and Business Overview
Table 142. AbbVie Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 143. AbbVie Inc. Pelvic Cancer Drug Product
Table 144. AbbVie Inc. Recent Developments/Updates
Table 145. Siemens Healthineers Company Information
Table 146. Siemens Healthineers Description and Business Overview
Table 147. Siemens Healthineers Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 148. Siemens Healthineers Pelvic Cancer Drug Product
Table 149. Siemens Healthineers Recent Developments/Updates
Table 150. Gilead Sciences, Inc. Company Information
Table 151. Gilead Sciences, Inc. Description and Business Overview
Table 152. Gilead Sciences, Inc. Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 153. Gilead Sciences, Inc. Pelvic Cancer Drug Product
Table 154. Gilead Sciences, Inc. Recent Developments/Updates
Table 155. Sanofi Company Information
Table 156. Sanofi Description and Business Overview
Table 157. Sanofi Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 158. Sanofi Pelvic Cancer Drug Product
Table 159. Sanofi Recent Developments/Updates
Table 160. Bayer AG Company Information
Table 161. Bayer AG Description and Business Overview
Table 162. Bayer AG Pelvic Cancer Drug Sales (kg), Revenue (US$ Million), Price (US$/g), and Gross Margin (2021–2026)
Table 163. Bayer AG Pelvic Cancer Drug Product
Table 164. Bayer AG Recent Developments/Updates
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Pelvic Cancer Drug Distributors List
Table 168. Pelvic Cancer Drug Customers List
Table 169. Pelvic Cancer Drug Market Trends
Table 170. Pelvic Cancer Drug Market Drivers
Table 171. Pelvic Cancer Drug Market Challenges
Table 172. Pelvic Cancer Drug Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
Table 176. Authors List of This Report
List of Figures
Figure 1. Product Picture of Pelvic Cancer Drug
Figure 2. Global Pelvic Cancer Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Pelvic Cancer Drug Market Share by Type: 2025 & 2032
Figure 4. Kidney Cancer Product Picture
Figure 5. Uterus Cancer Product Picture
Figure 6. Cervical Cancer Product Picture
Figure 7. Global Pelvic Cancer Drug Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Pelvic Cancer Drug Market Share by Application: 2025 & 2032
Figure 9. Chemotherapy
Figure 10. Radiation Therapy
Figure 11. Targeted Therapy
Figure 12. Global Pelvic Cancer Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Pelvic Cancer Drug Market Size (US$ Million), 2021–2032
Figure 14. Global Pelvic Cancer Drug Sales (kg), 2021–2032
Figure 15. Global Pelvic Cancer Drug Average Price (US$/g), 2021–2032
Figure 16. Pelvic Cancer Drug Report Years Considered
Figure 17. Pelvic Cancer Drug Sales Share by Manufacturers in 2025
Figure 18. Global Pelvic Cancer Drug Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Pelvic Cancer Drug Players: Market Share by Revenue in Pelvic Cancer Drug in 2025
Figure 20. Pelvic Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Pelvic Cancer Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Pelvic Cancer Drug Sales Market Share by Country (2021–2032)
Figure 23. North America Pelvic Cancer Drug Revenue Market Share by Country (2021–2032)
Figure 24. United States Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Pelvic Cancer Drug Sales Market Share by Country (2021–2032)
Figure 27. Europe Pelvic Cancer Drug Revenue Market Share by Country (2021–2032)
Figure 28. Germany Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Pelvic Cancer Drug Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Pelvic Cancer Drug Revenue Market Share by Region (2021–2032)
Figure 35. China Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Pelvic Cancer Drug Sales Market Share by Country (2021–2032)
Figure 43. Latin America Pelvic Cancer Drug Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Pelvic Cancer Drug Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Pelvic Cancer Drug Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Pelvic Cancer Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Pelvic Cancer Drug by Type (2021–2032)
Figure 54. Global Revenue Market Share of Pelvic Cancer Drug by Type (2021–2032)
Figure 55. Global Pelvic Cancer Drug Price (US$/g) by Type (2021–2032)
Figure 56. Global Sales Market Share of Pelvic Cancer Drug by Application (2021–2032)
Figure 57. Global Revenue Market Share of Pelvic Cancer Drug by Application (2021–2032)
Figure 58. Global Pelvic Cancer Drug Price (US$/g) by Application (2021–2032)
Figure 59. Pelvic Cancer Drug Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
